Drugs / LMY-922
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07679919 | Sep 2026 → Apr 2029 expected | hairy cell leukemia, plasma cell myeloma | Luminary Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMY-922 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07679919 ↗ |
| Action | Deplete | “to eliminate malignant B cells” NCT07679919 ↗ |
| Modality | Cell therapy | “LMY-922 is an allogeneic CAR-T cell therapy” NCT07679919 ↗ |